Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Sznol

Showing results (81-90 of 188) with videos related to

Pageof 19
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 13, 2013
Programmed death ligand-1 expression in non-small cell lung cancerVamsidhar Velcheti, Kurt A Schalper, Daniel E Carvajal, et al.
The Oncologist|November 25, 2025
Survival of patients with metastatic renal cell carcinoma with or without brain metastasesNoam Savion-Gaiger, Bryden Considine, Nitzan Hasson, et al.
Pigment Cell & Melanoma Research|February 16, 2011
In vitro studies of dasatinib, its targets and predictors of sensitivityLucia B Jilaveanu, Christopher R Zito, Saadia A Aziz, et al.
Frontiers in Oncology|March 30, 2022
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary FunctionShlomit Jessel, Sarah A Weiss, Matthew Austin, et al.
Frontiers in Oncology|February 21, 2024
Immunotherapy utilization in stage IIIA melanoma: less may be moreAlexander E Frey, Daniel M Kerekes, Sajid A Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12Charles F Eisenbeis, Gregory B Lesinski, Mirela Anghelina, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
BMJ Open Ophthalmology|January 20, 2022
Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic reviewJacob S Heng, Jenna M Kim, D Kyle Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanomaMary M McCarthy, Kyle A DiVito, Mario Sznol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint InhibitorsHarriet M Kluger, Christopher R Zito, Gabriela Turcu, et al.
Pageof 19

Showing results (81-90 of 188) with videos related to

Sort By:
Pageof 19
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 13, 2013
Programmed death ligand-1 expression in non-small cell lung cancerVamsidhar Velcheti, Kurt A Schalper, Daniel E Carvajal, et al.
The Oncologist|November 25, 2025
Survival of patients with metastatic renal cell carcinoma with or without brain metastasesNoam Savion-Gaiger, Bryden Considine, Nitzan Hasson, et al.
Pigment Cell & Melanoma Research|February 16, 2011
In vitro studies of dasatinib, its targets and predictors of sensitivityLucia B Jilaveanu, Christopher R Zito, Saadia A Aziz, et al.
Frontiers in Oncology|March 30, 2022
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary FunctionShlomit Jessel, Sarah A Weiss, Matthew Austin, et al.
Frontiers in Oncology|February 21, 2024
Immunotherapy utilization in stage IIIA melanoma: less may be moreAlexander E Frey, Daniel M Kerekes, Sajid A Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12Charles F Eisenbeis, Gregory B Lesinski, Mirela Anghelina, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
BMJ Open Ophthalmology|January 20, 2022
Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic reviewJacob S Heng, Jenna M Kim, D Kyle Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanomaMary M McCarthy, Kyle A DiVito, Mario Sznol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint InhibitorsHarriet M Kluger, Christopher R Zito, Gabriela Turcu, et al.
Pageof 19